Information Provided By:
Fly News Breaks for May 31, 2018
NVS, SBBP, CORT
May 31, 2018 | 07:33 EDT
As previously reported, Stifel analyst Adam Walsh downgraded Corcept Therapeutics (CORT) to Hold from Buy, noting that results are due near-term for both Strongbridge Biopharma's (SBBP) Recorlev and Novartis' (NVS) osilodrostat. While he does not have a clear read on the potential for positive outcomes for these candidates, Walsh thinks the impending read outs could create an overhang for Corcept shares, he tells investors. The analyst, who also notes a lack of FDA clarity on the Phase 3 trial design for Corcept's second-gen Cushing's candidate relacorilant, keeps a $20 price target on Corcept shares.
News For CORT;SBBP;NVS From the Last 2 Days
There are no results for your query CORT;SBBP;NVS